Market capitalization | $61.33m |
Enterprise Value | $-48.51m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.62 |
P/B ratio (TTM) P/B ratio | 0.56 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-89.13m |
Free Cash Flow (TTM) Free Cash Flow | $-78.32m |
EPS (TTM) EPS | $-1.59 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Connect Biopharma Holdings Ltd - ADR:
1 Analyst has issued a forecast Connect Biopharma Holdings Ltd - ADR:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.03 -1.03 |
0%
0%
|
|
EBITDA | -88 -88 |
0%
0%
|
EBIT (Operating Income) EBIT | -89 -89 |
0%
0%
|
Net Profit | -87 -87 |
0%
0%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.
Head office | Cayman Islands |
CEO | Barry Quart |
Employees | 81 |
Founded | 2015 |
Website | www.connectbiopharm.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.